Pages that link to "Q37656304"
Jump to navigation
Jump to search
The following pages link to Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium (Q37656304):
Displaying 13 items.
- Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer (Q34249190) (← links)
- Molecular pathways and targets in prostate cancer (Q34365632) (← links)
- Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. (Q34495028) (← links)
- Drug affinity responsive target stability (DARTS) for small-molecule target identification (Q35548750) (← links)
- Are androgen receptor variants a substitute for the full-length receptor? (Q38350089) (← links)
- The novel role of pyrvinium in cancer therapy. (Q38684406) (← links)
- Synthesis and evaluation of novel thiazole-based derivatives as selective inhibitors of DNA-binding domain of the androgen receptor. (Q38698469) (← links)
- Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription (Q38711524) (← links)
- Complex HuR function in pancreatic cancer cells (Q49922188) (← links)
- Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. (Q53126460) (← links)
- Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain (Q60015421) (← links)
- Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium (Q64253591) (← links)
- Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma (Q89947575) (← links)